{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=laronidase",
    "query": {
      "intervention": "laronidase"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=laronidase&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T18:20:12.540Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00144768",
      "title": "A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Mucopolysaccharidosis I",
        "Hurler's Syndrome",
        "Hurler-Scheie Syndrome",
        "Scheie's Syndrome"
      ],
      "interventions": [
        {
          "name": "laronidase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 25,
      "start_date": "2004-07",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2014-05-05",
      "last_synced_at": "2026-09-06T18:20:12.540Z",
      "location_count": 3,
      "location_summary": "Los Angles, California • Hartford, Connecticut • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Los Angles",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00144768"
    },
    {
      "nct_id": "NCT00912925",
      "title": "Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mucopolysaccharidosis I",
        "Hurlers Syndrome",
        "Hurler-Scheie Syndrome"
      ],
      "interventions": [
        {
          "name": "rhIDU (recombinant human-Alpha-L-Iduronidase)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2000-12",
      "completion_date": "2001-09",
      "has_results": true,
      "last_update_posted_date": "2015-04-07",
      "last_synced_at": "2026-09-06T18:20:12.540Z",
      "location_count": 2,
      "location_summary": "New York, New York • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00912925"
    },
    {
      "nct_id": "NCT02232477",
      "title": "Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS I",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mucopolysaccharidosis I",
        "Cognitive Decline"
      ],
      "interventions": [
        {
          "name": "Intrathecal recombinant human alpha iduronidase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "agnes chen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2014-08",
      "completion_date": "2020-02",
      "has_results": true,
      "last_update_posted_date": "2023-10-31",
      "last_synced_at": "2026-09-06T18:20:12.540Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02232477"
    },
    {
      "nct_id": "NCT01572636",
      "title": "Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mucopolysaccharidosis Type IH",
        "MPS I",
        "Hurler Syndrome"
      ],
      "interventions": [
        {
          "name": "Laronidase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2012-03-28",
      "completion_date": "2018-05-01",
      "has_results": false,
      "last_update_posted_date": "2018-09-27",
      "last_synced_at": "2026-09-06T18:20:12.540Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01572636"
    },
    {
      "nct_id": "NCT00146770",
      "title": "Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mucopolysaccharidosis I",
        "Hurler's Syndrome",
        "Hurler-Scheie Syndrome",
        "Scheie Syndrome"
      ],
      "interventions": [
        {
          "name": "Aldurazyme",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 45,
      "start_date": "2001-05",
      "completion_date": "2005-03",
      "has_results": true,
      "last_update_posted_date": "2015-04-03",
      "last_synced_at": "2026-09-06T18:20:12.540Z",
      "location_count": 8,
      "location_summary": "Mobile, Alabama • Atlanta, Georgia • Rochester, New York + 5 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00146770"
    },
    {
      "nct_id": "NCT01173016",
      "title": "Administration of IV Laronidase Post Bone Marrow Transplant in Hurler",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hurler Syndrome"
      ],
      "interventions": [
        {
          "name": "Laronidase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "Up to 14 Years"
      },
      "enrollment_count": 11,
      "start_date": "2012-05-29",
      "completion_date": "2016-03-04",
      "has_results": true,
      "last_update_posted_date": "2020-03-20",
      "last_synced_at": "2026-09-06T18:20:12.540Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01173016"
    },
    {
      "nct_id": "NCT05634512",
      "title": "Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hematopoietic Cell Transplantation",
        "Mucopolysaccharidosis Type I"
      ],
      "interventions": [
        {
          "name": "Laronidase therapy and a stem cell transplant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "3 Years",
        "sex": "ALL",
        "summary": "0 Years to 3 Years"
      },
      "enrollment_count": 13,
      "start_date": "2022-11-17",
      "completion_date": "2026-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-09-06T18:20:12.540Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05634512"
    },
    {
      "nct_id": "NCT00176891",
      "title": "Stem Cell Transplant w/Laronidase for Hurler",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mucopolysaccharidosis I",
        "Hurler Syndrome"
      ],
      "interventions": [
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Laronidase ERT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "7 Years",
        "sex": "ALL",
        "summary": "Up to 7 Years"
      },
      "enrollment_count": 25,
      "start_date": "2004-03",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2019-07-11",
      "last_synced_at": "2026-09-06T18:20:12.540Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176891"
    },
    {
      "nct_id": "NCT00215527",
      "title": "Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mucopolysaccharidosis I",
        "Lysosomal Storage Diseases",
        "Spinal Cord Compression"
      ],
      "interventions": [
        {
          "name": "laronidase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Patricia I. Dickson, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2005-11",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2013-02-21",
      "last_synced_at": "2026-09-06T18:20:12.540Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00215527"
    },
    {
      "nct_id": "NCT04532047",
      "title": "PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "MPS I",
        "MPS II",
        "MPS IVA",
        "MPS VI",
        "Mps VII",
        "Gaucher Disease, Type 2",
        "Gaucher Disease, Type 3",
        "Pompe Disease Infantile-Onset",
        "Wolman Disease"
      ],
      "interventions": [
        {
          "name": "Aldurazyme (laronidase)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2021-07-01",
      "completion_date": "2032-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-09-06T18:20:12.540Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04532047"
    }
  ]
}